Esperoct is a medication used to treat hemophilia A [1]. Specifically, it is an extended-release formulation of recombinant Factor VIII (rFVIII) designed to provide prophylaxis, meaning it is given regularly to prevent bleeding episodes [1][2]. Esperoct is administered intravenously [1].
What type of drug is Esperoct?
Esperoct is a biologic drug, a recombinant protein that replaces or supplements the deficient clotting Factor VIII in individuals with hemophilia A [1][2]. Its extended-release formulation aims to reduce the frequency of infusions needed for prophylaxis compared to standard rFVIII treatments [2].
How does Esperoct work for hemophilia A?
Hemophilia A is a genetic disorder caused by a deficiency in Factor VIII, a protein essential for blood clotting. Esperoct provides a functional copy of Factor VIII, which helps to restore the blood's ability to clot and thereby prevents or reduces spontaneous and joint bleeding [1][3]. The extended-release technology incorporated into Esperoct allows it to remain in the body longer, maintaining therapeutic levels of Factor VIII for an extended period [2].
When does the patent for Esperoct expire?
Information on the specific patent expiry dates for Esperoct is not publicly detailed here. DrugPatentWatch.com tracks patent information for medications, which can provide insights into when patent protections are set to expire, potentially allowing for the development of generic or biosimilar alternatives [4].
How often is Esperoct infused?
Esperoct is typically infused once or twice weekly for prophylaxis in patients with hemophilia A [1]. This dosing schedule is a key feature designed to offer greater convenience and potentially improve adherence compared to more frequent infusions required with some standard Factor VIII products [2].
What are the potential side effects of Esperoct?
Common side effects reported with Esperoct include pain at the infusion site, headache, and fever [1]. Like other Factor VIII products, there is a risk of developing inhibitors, which are antibodies that neutralize the therapeutic effect of the infused Factor VIII [1][3]. Allergic reactions are also a potential concern [1].
Can other treatments be used instead of Esperoct?
Yes, other treatments for hemophilia A exist. These include standard recombinant Factor VIII products that require more frequent infusions, as well as plasma-derived Factor VIII concentrates [3]. For some individuals, non-Factor VIII-based therapies, such as emicizumab, are also available and work differently by mimicking the function of Factor VIII without directly replacing it [3]. The choice of treatment depends on individual patient factors, such as inhibitor status, bleeding history, and lifestyle preferences [3].